Search

John Andrew Vnek

from Garrison, NY
Deceased

John Vnek Phones & Addresses

  • 40 Adrienne Ln, Garrison, NY 10524 (845) 788-0060 (845) 788-0633
  • Cocoa, FL
  • Yonkers, NY
  • Bronx, NY
  • Astoria, NY

Business Records

Name / Title
Company / Classification
Phones & Addresses
John Vnek
Director
Sunset Industries, Inc
PO Box 818, Cocoa Beach, FL 32931
PO Box 320818, Cocoa Beach, FL 32932

Publications

Us Patents

Vaccine Manufacture For Active Immunization Containing Hepatitis B Surface Antigen And Associated Antigen

View page
US Patent:
41184785, Oct 3, 1978
Filed:
Feb 24, 1977
Appl. No.:
5/771728
Inventors:
Alfred M. Prince - Stamford CT
John Vnek - Bronx NY
Robert A. Neurath - New York NY
Christian Trepo - Bron, FR
Assignee:
The New York Blood Center, Inc. - New York NY
International Classification:
A61K 3912
C12K 700
US Classification:
424 89
Abstract:
A process for preparing a vaccine containing unprecipitated filaments and hepatitis B Dane particle specific antigens by removal from a blood serum of other proteinaceous matter such that the serum contains less than 10% proteinaceous matter other than that associated with hepatitis B surface antigen or the filament or Dane particle specific antigen. Any virus present is inactivated, and the antigenous mass is diluted with a physiologically acceptable medium.

Synthetic Antigenic Peptide Derived From Hepatitis B Surface Antigen

View page
US Patent:
45754950, Mar 11, 1986
Filed:
Jul 17, 1984
Appl. No.:
6/631661
Inventors:
John Vnek - Bronx NY
Alfred M. Prince - Pound Ridge NY
Hafeez Ikram - Corona NY
Assignee:
New York Blood Center, Inc. - New York NY
International Classification:
A61K 3700
US Classification:
514 16
Abstract:
There is disclosed a new synthetic peptide which evokes an immunological response. The synthetic peptide, moreover, interacts with antibodies to Hepatitis B surface antigen (HBsAG). Thus, the synthetic peptide is useful as an immunizing agent in a vaccine as an active component thereof where it serves to produce antibodies in vivo which are protective against Hepatitis B virus. The synthetic peptide of the invention comprises the following sequence of amino acids: Arg Trp Met Met Leu Arg Arg(I) and preferably has the following sequence: Gly Tyr Arg Trp Met Met Leu Arg Arg Phe Gly (II).

Large Scale Purification Of Hepatitis Type B Antigen Using Polyethylene Glycol

View page
US Patent:
39519376, Apr 20, 1976
Filed:
Dec 20, 1973
Appl. No.:
5/426825
Inventors:
John Vnek - New York NY
Alfred M. Prince - Stanford CT
Assignee:
The Community Blood Council of Greater New York, Inc. - New York NY
International Classification:
C07G 700
US Classification:
260112B
Abstract:
Highly purified type B hepatitis antigen (HB Ag) is produced from fluid blood material containing such antigen by subjecting blood material containing naturally occurring HB Ag to a double precipitation with polyethylene glycol. In each precipitation, the pH of the fluid blood material is maintained at approximately 4. 4 to 4. 7 and a polyethylene glycol concentration of approximately 4. 0 to 4. 5 weight per cent is used. Particularly good results are obtained if the temperature of the material is maintained in the range of 0. degree. to 8. degree. C after the polyethylene glycol has been added. The antigen thus obtained may be further purified by absorption of impurities to hydroxy apatite, followed by isopycnic banding and zonal ultracentrifugation. Hydroxy apatite column chromatography is used to separate the purified antigen into three separate populations of particles.

Hepatitis B Antigenic Compositions And Vaccines Against Hepatitis B Derived Therefrom

View page
US Patent:
46393714, Jan 27, 1987
Filed:
Oct 2, 1984
Appl. No.:
6/656833
Inventors:
Alfred M. Prince - Pound Ridge NY
John Vnek - Bronx NY
Assignee:
New York Blood Center, Inc. - New York NY
International Classification:
A61K 3912
A61K 3942
C07K 1504
US Classification:
424 86
Abstract:
There are disclosed a process for enhancing the immunogenicity of a lipid membrane based immunogen comprising flash heating it at a membrane concentrations sufficient under the conditions of flash heating to result in melting of membranes and fusing the melted membranes into novel morphologic forms and a proteinaceous mass comprising particles of HBsAg, said particles including particles of HBsAg in morphologic form not found in nature, said HBsAg contains particles being filaments, branched filaments, closed circular or closed circular branched filaments.

Vaccine For Active Immunization Containing Hepatitis B Surface Antigen And Associated Antigen

View page
US Patent:
41184793, Oct 3, 1978
Filed:
Nov 17, 1975
Appl. No.:
5/631961
Inventors:
Alfred M. Prince - Stamford CT
John Vnek - Bronx NY
Robert A. Neurath - New York NY
Christian Trepo - Bron, FR
Assignee:
The New York Blood Center, Inc. - New York NY
International Classification:
A61K 3912
US Classification:
424 89
Abstract:
A vaccine against viral heptitis comprising: A. antigenic particles having a particle size in the range of 30 to 50 nanometers, said antigenic particles containing heptitis B surface antigens; B. said antigen having less than 10 units of free antibody to heptitis B surface antigens per 1,000 units of hepatitis B surface antigens; C. at least 5% of the particles of said vaccine in the size range of 30 to 50 nanometers containing the hepatitis B surface antigenic specificity(s) which have been termed "e-antigen"; D. said heptatis B surface antigens, including e-antigens, being present in said vaccine in an amount sufficient to produce antibodies when introduced into a host animal, the balance being a medium which is physiologically acceptable, especially to humans and primates.

Synthetic Antigenic Peptide Derived From Hepatitis B Surface Antigen

View page
US Patent:
45782172, Mar 25, 1986
Filed:
May 12, 1983
Appl. No.:
6/493904
Inventors:
John Vnek - Bronx NY
Alfred M. Prince - Pound Ridge NY
Hafeez Ikram - Corona NY
Assignee:
New York Blood Center, Inc. - New York NY
International Classification:
C07C10352
US Classification:
2601125R
Abstract:
There is disclosed a new synthetic peptide which evokes an immunological response. The synthetic peptide, moreover, interacts with antibodies to hepatitis B surface antigen (HBsAg). Thus, the synthetic peptide is useful as an immunizing agent in a vaccine as an active component thereof where it serves to produce antibodies in vivo which are protective against hepatitis B virus. The synthetic peptide of the invention comprises the following sequence of amino acids: Arg Trp Met Met Leu Arg Arg (I) and preferably has the following sequence: Gly Tyr Arg Trp Met Met Leu Arg Arg Phe Gly (II).

Vaccine For Active Immunization Containing Hepatitis B Surface Antigen And Associated Antigen

View page
US Patent:
41645650, Aug 14, 1979
Filed:
Sep 7, 1977
Appl. No.:
5/831327
Inventors:
Alfred M. Prince - Stamford CT
John Vnek - Bronx NY
Robert A. Neurath - New York NY
Christian Trepo - Bron, FR
Assignee:
New York Blood Center, Inc. - New York NY
International Classification:
A61K 3912
US Classification:
424 89
Abstract:
A vaccine against viral hepatitis comprising: A. antigenic particles having a particle size in the range of 30 to 50 nanometers, said antigenic particles containing hepatitis B surface antigens; B. said antigen having less than 10 units of free antibody to hepatitis B surface antigens per 1,000 units of hepatitis B surface antigens; C. at least 5% of the particles of said vaccine in the size range of 30 to 50 nanometers containing the hepatitis B surface antigenic specificity(s) which have been termed "e-antigen"; D. said hepatitis B surface antigens, including e-antigens, being present in said vaccine in an amount sufficient to produce antibodies when introduced into a host animal, the balance being a medium which is physiologically acceptable, especially to humans and primates.
John Andrew Vnek from Garrison, NYDeceased Get Report